TRB
Live / Registered — Registered (as of 02 Feb 2021)
What this means for you
Registered since 02 Feb 2021. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79284012
- Registration number
- 6258760
- Mark type
- Design + words
- Filed
- 11 Mar 2020
- Published for opposition
- 17 Nov 2020
- Registered
- 02 Feb 2021
- Attorney of record
- Andrew M. Smith
Goods and services
- Class 005 — Pharmaceuticals: pharmaceuticals, namely, anti-neurodegenerative, anti-neurotrophic, anti-antineurotoxic, neuroprotective and neurorestorative effect agents; pharmaceuticals, namely, immunopharmaceuticals; medical and veterinary preparations, namely, preparations for use in treating joint disease in horses, and antioxidants; pharmaceutical and medicinal preparations and substances for treating and preventing ophthalmic, ocular, neurological, metabolic, dermatological, arthritic, cognitive, or sexual dysfunction-related conditions, disorders or diseases; pharmaceutical and medicinal preparations and substances for treating and preventing joint, ligament, tendon, cartilage, bone, damaged skin or tissue-related conditions, disorders or diseases; pharmaceutical and medicinal preparations and substances for the treatment of central or peripheral nervous system-related, spinal cord-related, or early stages of traumatic or acute vascular injury-related disorders and diseases; pharmaceutical and medicinal preparations and substances for the treatment of pain, inflammation, physical lesions, and wounds; analgesics; anti-inflammatories; medicines for the treatment of keratitis, Sjögren's syndrome or primary dry eye syndrome; medicines for use as surgical aid during cataract surgery procedures; medicines for the treatment of osteoarthritis and rheumatoid arthritis; medicines for the prevention of osteoporosis; medicines for the treatment of musculo-skeletal conditions, disorders or diseases; medicines for the treatment of tendinopathy; medicines for joint recovery after arthroscopy; medicines to help assist with the regeneration of ligament and tendon fibers; medicines for the treatment of immune system related diseases and disorders; medicines for the treatment of blepharitis, glaucoma, and degenerative eye pathologies; pharmaceutical drugs for the treatment of keratitis, Sjögren's syndrome or primary dry eye syndrome; pharmaceutical drugs for use as surgical aid during cataract surgery procedures; pharmaceutical drugs for the treatment of osteoarthritis and rheumatoid arthritis; pharmaceutical drugs for the prevention of osteoporosis; pharmaceutical drugs for the treatment of musculo-skeletal conditions, disorders or diseases; pharmaceutical drugs for the treatment of tendinopathy; pharmaceutical drugs for joint recovery after arthroscopy; pharmaceutical drugs to help assist with the regeneration of ligament and tendon fibers; pharmaceutical drugs for the treatment of immune system related diseases and disorders; pharmaceutical drugs for the treatment of blepharitis, glaucoma, and degenerative eye pathologies; therapeutic drugs for the treatment of keratitis, Sjögren's syndrome or primary dry eye syndrome; therapeutic drugs for use as surgical aid during cataract surgery procedures; therapeutic drugs for the treatment of osteoarthritis and rheumatoid arthritis; therapeutic drugs for the prevention of osteoporosis; therapeutic drugs for the treatment of musculo-skeletal conditions, disorders or diseases; therapeutic drugs for the treatment of tendinopathy; therapeutic drugs for joint recovery after arthroscopy; therapeutic drugs to help assist with the regeneration of ligament and tendon fibers; therapeutic drugs for the treatment of immune system related diseases and disorders, and therapeutic agents for the treatment of keratitis, Sjögren's syndrome or primary dry eye syndrome; therapeutic agents for use as surgical aid during cataract surgery procedures; therapeutic agents for the treatment of osteoarthritis and rheumatoid arthritis; therapeutic agents for the prevention of osteoporosis; therapeutic agents for the treatment of musculo-skeletal conditions, disorders or diseases; therapeutic agents for the treatment of tendinopathy; therapeutic agents for joint recovery after arthroscopy; therapeutic agents to help assist with the regeneration of ligament and tendon fibers; therapeutic agents for the treatment of immune system related diseases and disorders; transdermal patches featuring vitamins for increasing energy for medical use; biological cartilage, bone or skin tissue intended for subsequent implantation; biological preparations for medical or veterinary use, namely, for the treatment of infectious diseases; sanitary preparations for medical purposes; dietetic food and substances in the nature of food supplements and vitamins supplements all adapted for medical or veterinary use; food for babies; dietary supplements for humans and animals; meal replacements, namely, meal replacement bars adapted for medical use and meal replacement beverages adapted for medical use, and dietetic beverages adapted for medical and veterinary use; materials for dressings, namely, dressings for wounds, burns or surgery, adhesive bandages, gauze for dressings, pledgets; disinfectants
Owner
Prior registrations
Prosecution history
- 02 Feb 2026 — COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
- 26 Nov 2025 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 26 Nov 2025 — NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
- 18 Sept 2024 — CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED
- 30 Jun 2024 — CORRECTION TRANSACTION RECEIVED FROM IB
- 09 Jun 2024 — CHANGE OF NAME/ADDRESS REC'D FROM IB
- 26 Feb 2023 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 26 Feb 2023 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 26 Feb 2023 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 30 May 2021 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 18 May 2021 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 18 May 2021 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 18 May 2021 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 05 May 2021 — FINAL DISPOSITION NOTICE SENT TO IB
- 05 May 2021 — FINAL DISPOSITION PROCESSED